Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
Frontiers in Cardiovascular Medicine · 17.03.2025 · 12
DOI: 10.3389/fcvm.2025.1542870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 17.03.2025. Verfasst von Massimo Mapelli und 21 weiteren Autor:innen. Beteiligte Einrichtung: Centro Cardiologico Monzino, IRCCS, Milan, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) are standard therapy for heart failure (HF). We performed a holistic evaluation of dapagliflozin, including its effects on exercise performance, left ventricle (LV) reverse remodeling, cardiac biomarkers, fluid retention, and renal and pulmonary function.
Methods
We enrolled HF reduced ejection fraction (LVEF) outpatients (EF <40%) eligible for SGLT2-i and performed cardiopulmonary exercise tests (CPET), pulmonary function tests, bioelectrical impedance vector analysis, and laboratory and echocardiographic assessments at baseline ( T = 0), after 2–4 weeks (T1), and after 6 months of treatment (T2).
Results
None of the patients interrupted SGLT2-i for adverse events albeit follow-up was completed by 67 of 75 enrolled patients. At T2, mean LVEF increased (from 34.6 ± 7.8 to 37.5 ± 9.2%; p < 0.001) while end-diastolic (EDV) and end-systolic (ESV) volumes decreased [EDV: 186 (145–232) vs. 177 (129–225) mL, ESV: 113 (87–163) vs. 110 (76–145) mL; p < 0.001]. Peak oxygen intake was unchanged [peakVO 2 : 16.2 (13.4–18.7) vs. 16.0 (13.3–18.9) mL/kg/min; p = 0.297], while exercise ventilatory efficiency (VE/VCO 2 slope) improved [from 34.2 (31.1–39.2) to 33.7 (30.2–37.6); p = 0.006]. Mean hemoglobin increased (from 13.8 ± 1.5 to 14.6 ± 1.7 g/dL; p < 0.001), while renal function did not change after a transient worsening at T1. NT-proBNP, ST-2, and hs-TNI did not change as overall body fluids and quality of life assessed by KCCQ. NYHA class improved ( p =0.002), paralleled by a decrease of MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) score, from 3.3% (1.9–8.0) to 2.8% (1.2–5.7), suggestive of a positive impact on 2 years prognosis ( p < 0.001).
Conclusions
Dapagliflozin induced positive LV remodeling, improvement of exercise ventilatory efficiency, and NYHA class but without peakVO 2 fluid status and cardiac biomarkers changes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro Cardiologico Monzino, IRCCS, Milan, Italy.
- Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy.
- Cardiovascular Department, "Azienda Sanitaria Universitaria Giuliano-Isontina," Trieste, Italy.
- Cardiology Division, Nostra Signora di Bonaria Hospital, San Gavino Monreale, Italy.
- Department of Cardiology, Casa di Cura Tortorella, Salerno, Italy.
Zitieren
APA
Mapelli, M., Mattavelli, I., Salvioni, E., Capra, N., Mantegazza, V., Garlaschè, A., Campodonico, J., Rubbo, F. M., Paganin, C., Capovilla, T. M., Nepitella, A. A., Caputo, R., Gugliandolo, P., Vignati, C., Pezzuto, B., De Martino, F., Grilli, G., Scatigna, M., Bonomi, A., …, & Agostoni, P. (2025). Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1542870
Vancouver
Mapelli M, Mattavelli I, Salvioni E, Capra N, Mantegazza V, Garlaschè A, et al. Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1542870
BibTeX
@article{Mapelli2025,
author = {Mapelli, Massimo and Mattavelli, Irene and Salvioni, Elisabetta and Capra, Nicolò and Mantegazza, Valentina and Garlaschè, Anna and Campodonico, Jeness and Rubbo, Filippo Maria and Paganin, Chiara and Capovilla, Teresa Maria and Nepitella, Alessandro Alberto and Caputo, Rebecca and Gugliandolo, Paola and Vignati, Carlo and Pezzuto, Beatrice and De Martino, Fabiana and Grilli, Giulia and Scatigna, Marco and Bonomi, Alice and Sinagra, Gianfranco and Muratori, Manuela and Agostoni, Piergiuseppe},
title = {Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?},
journal = {Frontiers in Cardiovascular Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fcvm.2025.1542870}
}
EUVIMED